Organization
The WIN Consortium is organized in the following groups who collectively work together to achieve WIN's common goals
“New Leadership, vision for the Worldwide Innovative Network Consortium in Precision Oncology” View Summary
WINning together
WIN was formed on the premise that we can accomplish more together than each organization can achieve working alone. We aim to improve cancer patients’ survival and quality of life. View WIN's history and unique attributes:
-
01
WIN History -
02
Diversity of Stakeholders - WIN Members -
03
Studies with a global population -
04
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN represents a global collaboration of cancer centers, life science and biotech organizations, and technology companies and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 34 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, Middle East and Australia.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 34 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, Middle East and Australia.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.
Our members include leading academic, life science, not-for-profit, health, patient advocacy and IT organizations.
Our members include leading academic, life science, not-for-profit, health, patient advocacy and IT organizations.
Our members include 27 leading academic centers representing 18 countries and five continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.
WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually, brings together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.
Clinical trials, projects and publications
WIN members collaboratively design and carry out global studies designed to achieve breakthroughs for patients worldwide. Our distinguished Scientific Advisory Board oversees WIN studies. Current trials include:
-
01
Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors -
02
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments -
03
SPRING - Landmark Lung Cancer Tri-Therapy Clinical Trial -
04
WINTHER: the WIN Consortium's first global personalized medicine clinical trial, published in Nature Medicine
Considering the hypothesis that central hubs are associated with increased lethality, identifying key hub targets within central networks could lead to the development of novel drugs with improved efficacy in advanced metastatic solid tumors.
October 19, 2024
Published by Therapeutic Advances in Medical Oncology
Abstract
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options.
Objective: Considering the hypothesis that central hubs are associated with increased
lethality, identifying key hub targets within central networks could lead to the development of novel drugs with improved efficacy in advanced metastatic solid tumors.
Design: Exploring transcriptomic data (22,000 gene products) from the WINTHER trial (N = 101 patients with various metastatic cancers), in which both tumor and normal organ-matched tissue were available.
Methods: A retrospective in silico analysis of all genes in the transcriptome was conducted to identify genes different in expression between tumor and normal tissues (paired t-test) and to determine their association with survival outcomes using survival analysis (Cox proportional
hazard regression algorithm). Based on the biological relevance of the identified genes, hub targets of interest within central networks were then pinpointed. Patients were grouped based on the expression level of these genes (K-mean clustering), and the association of these
groups with survival was examined (Cox proportional hazard regression algorithm, Forest plot, and Kaplan–Meier plot).
Results: We identified four key central hub genes—PLOD3, ARHGAP11A, RNF216, and CDCA8, for which high expression in tumor tissue compared to analogous normal tissue had the most significant correlation with worse outcomes. The correlation was independent of tumor or treatment type. The combination of the four genes showed the highest significance and correlation with the poorer outcome: overall survival (hazard ratio (95% confidence interval
(CI)) = 10.5 (3.43–31.9) p = 9.12E−07 log-rank test in a Cox proportional hazard regression model). Findings were validated in independent cohorts.
Conclusion: The expression of PLOD3, ARHGAP11A, RNF216, and CDCA8 constitute, when combined, a prognostic tool, agnostic of tumor type and previous treatments. These genes represent potential targets for intercepting central hub networks in various cancers, offering
avenues for novel therapeutic interventions.
Keywords: cancer, genes, prognostic markers, RNA, transcriptomic
Download pdf
Published by Therapeutic Advances in Medical Oncology
Abstract
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options.
Objective: Considering the hypothesis that central hubs are associated with increased
lethality, identifying key hub targets within central networks could lead to the development of novel drugs with improved efficacy in advanced metastatic solid tumors.
Design: Exploring transcriptomic data (22,000 gene products) from the WINTHER trial (N = 101 patients with various metastatic cancers), in which both tumor and normal organ-matched tissue were available.
Methods: A retrospective in silico analysis of all genes in the transcriptome was conducted to identify genes different in expression between tumor and normal tissues (paired t-test) and to determine their association with survival outcomes using survival analysis (Cox proportional
hazard regression algorithm). Based on the biological relevance of the identified genes, hub targets of interest within central networks were then pinpointed. Patients were grouped based on the expression level of these genes (K-mean clustering), and the association of these
groups with survival was examined (Cox proportional hazard regression algorithm, Forest plot, and Kaplan–Meier plot).
Results: We identified four key central hub genes—PLOD3, ARHGAP11A, RNF216, and CDCA8, for which high expression in tumor tissue compared to analogous normal tissue had the most significant correlation with worse outcomes. The correlation was independent of tumor or treatment type. The combination of the four genes showed the highest significance and correlation with the poorer outcome: overall survival (hazard ratio (95% confidence interval
(CI)) = 10.5 (3.43–31.9) p = 9.12E−07 log-rank test in a Cox proportional hazard regression model). Findings were validated in independent cohorts.
Conclusion: The expression of PLOD3, ARHGAP11A, RNF216, and CDCA8 constitute, when combined, a prognostic tool, agnostic of tumor type and previous treatments. These genes represent potential targets for intercepting central hub networks in various cancers, offering
avenues for novel therapeutic interventions.
Keywords: cancer, genes, prognostic markers, RNA, transcriptomic
Download pdf
“Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival”
WIN's article “Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival” published by NPJ Precision Oncology, a Nature Research journal.
SPRING 01 (Survival Prolongation by Rationale Innovative Genomics) proof of concept trial is the first trial exploring the tri-therapy strategy in first line of advanced/metastatic non-small cell lung cancer (NSCLC), following the historical success of this approach in AIDS and tuberculosis for which only tri-therapy demonstrated long term efficacy.
The WIN SPRING trial was conducted in the USA, France, Spain, Luxembourg and Israel in the following cancer centers: University of California - San Diego's Moores Cancer Center, Avera Cancer Center (Sioux Falls, Arizona), Institut Curie (Paris), Centre Léon Bérard (Lyon), Vall d'Hebron Institute of Oncology (Barcelona), Centre Hospitalier de Luxembourg (Luxembourg), and Chaim Sheba Medical Center (Israel).
The trial was sponsored by the WIN Consortium and funded by ARC Fondation for cancer research (France). The drugs were donated by Pfizer Inc.
The trial was sponsored by the WIN Consortium and funded by ARC Fondation for cancer research (France). The drugs were donated by Pfizer Inc.
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.
Published in Nature Medicine, results of WINTHER, the first study pioneered by the WIN Consortium.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial - shows that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling for tumor mutations alone.
People leadership
WIN leaders are selected for their contributions and commitment to making effective, personalized cancer medicine a reality for patients around the world. They guide WIN's strategic, operational, and scientific direction.
Organization
Chair, WIN Consortium
Wafik El-Deiry
Wafik El-Deiry
Chair, WIN Consortium; Director, Legorreta Cancer Center at Brown University (USA)
Chair Emeritus, WIN Consortium
Richard L. Schilsky
Richard L. Schilsky
Chair Emeritus, WIN Consortium; Professor Emeritus, University of Chicago; past President and former Executive Vice President & Chief Medical Officer (ASCO) (USA)
Chief Medical Officer, Executive Committee, WIN Consortium
Razelle Kurzrock
Razelle Kurzrock
Chief Medical Officer, WIN Consortium; Prof. of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes Chair of Precision Oncology (USA)
Director, Operational Team, WIN Consortium
Catherine Bresson
Catherine Bresson
Director, Operational Team, WIN Consortium
Our members and collaborators
WIN members include 34 leading organizations representing all stakeholders in personalized cancer medicine covering 18 countries and 5 continents. Our shared vision is delivering the promise of effective, personalized cancer medicine to patients worldwide. The WIN Consortium has collaborated with additional academic institutions and pharmaceutical partners in successful completion of global clinical trials in precision oncology.
WIN Symposia
WIN Symposia, held annually, gathers leaders representing a breadth of stakeholders from around the world to learn, share, and collaborate. Our latest symposium took place in Abu Dhabi, UAE, for further information, visit: win-burjeel-symposium.com/
Abstracts Presented at the 2024 WIN Symposium in Partnership with Burjeel Holdings March 1-2, 2024, Abu Dhabi, United Arab Emirates
March 01, 2024 - March 02, 2024The WIN Symposium 2024, a landmark event in precision oncology, took place in Abu Dhabi, United Arab Emirates (UAE), on the 1st and 2nd of March 2024; marking a significant collaboration between the Worldwide Innovative Network (WIN) Consortium and Burjeel Holdings. This annual global congress of the WIN Consortium brought together physicians, researchers, and scientists from 30 countries to explore the latest advancements in precision oncology, with the ultimate goal of improving cancer patient care and outcomes worldwide.
The call for abstracts attracted 51 submissions with 42 accepted as posters and 3 as oral presentations. This publication features 34 of the accepted abstracts.
The abstracts are now published online on the JIPO website:
https://meridian.allenpress.com/innovationsjournals-JIPO/article/doi/10.36401/JIPO-24-X2/500828/Abstracts-Presented-at-the-2024-WIN-Symposium-in
or can be downloaded from this section.
WIN 2024 Symposium
March 01, 2024 - March 02, 2024The two-day WIN Symposium 2024, organized by the WIN Consortium and hosted by Burjeel Holdings took place in Abu Dhabi, United Arab Emirates on 1-2 March 2024.
Under the theme of “Precision and Molecular Oncology: Caring for Patients and Future Generations,” the symposium brought together more than 450 expert clinicians, researchers and industry professionals from over 30 countries. Together, they explored the latest advances in precision oncology and offered insights into the developments shaping the future of oncology. The symposium started with an inspiring keynote lecture by Nobel Laureate Professor James Allison, who has revolutionized cancer immunotherapy. The curated programs featured interactive elements illustrating precision cancer treatment principles and best practices.
More than 50 abstracts were received from over 15 countries. The event was endorsed by the American Society of Clinical Oncology (ASCO®) and accredited for 8.5 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).
The WIN Symposium provided attendees with a deep understanding of the role of key biomarkers, their optimal application, and emerging new omic tests that will inform future biomarker adoption under the two big umbrellas of Precision Genomics and Precision Immunotherapy. Local experience from the UAE, the host country, was included to link global evidence to regional practice. Application of the principles of precision medicine were discussed beyond medical and onto radiation oncology along with issues of access, equity and diversity in precision oncology practice and trials on a global scale. The symposium featured a Molecular Tumor Board to exemplify with real patient cases how to use biomarkers to inform therapeutic choices. Finally, a panel discussion was dedicated to navigating available diagnostic pathways and tests from bench to bedside.
The symposium provided networking opportunities, allowing participants to connect with peers, establish collaborations, and forge new partnerships.
Visit our dedicated symposium website for all the details of this event: https://win-burjeel-symposium.com/.
ASCO® is a registered trademark of the American Society of Clinical Oncology®. Used with permission. This is not an ASCO sponsored event.
WIN 2022 Symposium
October 29, 2022 - October 30, 2022The WIN 2022 Symposium ‘Integrating Genomics and Transcriptomics to Reshape Precision Oncology: A WINning Strategy’ took place on 29-30 October, 2022 in Barcelona, Spain.
We had an exciting line-up of prominent speakers and panel discussion and our 1st international molecular board!
What people are saying
I am looking forward to expanding further the WIN membership with world-class cancer centers as well as diagnostics, biotech, and pharma companies. WIN represents a fabulous platform to launch compelling precision oncology and early diagnosis studies internationally building upon our experience in genomics and transcriptomics. We are looking forward to entering into partnership with drugs and omics companies as well as philanthropy to pursue our common objective to insure that all patients have access to precision cancer care and research studies. Wafik El-Deiry, WIN Chair
"WIN is an unique, global, translational clinical research organization with a bold vision to bring cutting edge science and technology to the cure of cancer worldwide. It is a privilege to help guide the organization as Chair Emeritus." Richard L. Schilsky, WIN Chair Emeritus
"Achieving much needed major clinical breakthroughs in cancer treatment requires bold thinking and action, a can do attitude and winning spirit, and close collaboration of stakeholders and contributors with diverse background and expertise. All this is epitomized by WIN." Vladimir Lazar, Chief Scientific and Operating Officer
Exploring Precision Oncology - Interview with Dr. Razelle Kurzrock, Chief Medical Officer and Dr. Sewanti Limaye at WIN 2022 Symposium (To view the video, scroll through this slider or go to the News section) JIPO and WIN Consortium
-
01
WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East. -
02
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment -
03
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients -
04
Cure51 Joins Worldwide Innovative Network (WIN) in Personalized Cancer Medicine Consortium - WIN Consortium
WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.
July 4, 2025 - WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East.
The GEMINI-NSCLC study generates a robust, multi-omic dataset for research in biomarker discovery. The study includes two patient cohorts:
- Patients diagnosed with Stage IV NSCLC receiving standard-of-care first-line checkpoint inhibitor therapy
- Patients with early-stage NSCLC who are candidates for surgery and perioperative treatment
Tempus deploys its comprehensive molecular profiling platform—including solid tumor (xT/xR) and liquid biopsy (xF)—to analyze tumor biology longitudinally in the study. The study focuses on understanding disease progression and treatment response, with emphasis on identifying novel biomarkers and the use of circulating tumor DNA (ctDNA) to monitor MRD.
The GEMINI-NSCLC study generates a robust, multi-omic dataset for research in biomarker discovery. The study includes two patient cohorts:
- Patients diagnosed with Stage IV NSCLC receiving standard-of-care first-line checkpoint inhibitor therapy
- Patients with early-stage NSCLC who are candidates for surgery and perioperative treatment
Tempus deploys its comprehensive molecular profiling platform—including solid tumor (xT/xR) and liquid biopsy (xF)—to analyze tumor biology longitudinally in the study. The study focuses on understanding disease progression and treatment response, with emphasis on identifying novel biomarkers and the use of circulating tumor DNA (ctDNA) to monitor MRD.
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment
June 17, 2025
Oncotarget, 2025, Vol.16, pp: 456-466
Precision Oncology
ABSTRACT
Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression.
WIN Consortium International Molecular Tumor Board (MTB), included experts from institutions across 13 countries. Enrollment in suitable clinical trials was explored but limited by availability. Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate EGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily. FOLFOXFIRI combined with bevacizumab, or liver-directed therapies for hepatic metastases, or regorafenib with 5FU, or crizotinib (MET inhibitor) combined with regorafenib or dabrafenib, was also suggested.
This case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC. The WIN International MTB aims to provide treatment and biomarker analysis discussion with the ultimate goal of optimizing treatment efficacy by targeting specific molecular alterations, though final treatment decisions remain at the discretion of the treating physician.
View the full article here: Download pdf
Oncotarget, 2025, Vol.16, pp: 456-466
Precision Oncology
ABSTRACT
Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression.
WIN Consortium International Molecular Tumor Board (MTB), included experts from institutions across 13 countries. Enrollment in suitable clinical trials was explored but limited by availability. Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate EGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily. FOLFOXFIRI combined with bevacizumab, or liver-directed therapies for hepatic metastases, or regorafenib with 5FU, or crizotinib (MET inhibitor) combined with regorafenib or dabrafenib, was also suggested.
This case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC. The WIN International MTB aims to provide treatment and biomarker analysis discussion with the ultimate goal of optimizing treatment efficacy by targeting specific molecular alterations, though final treatment decisions remain at the discretion of the treating physician.
View the full article here: Download pdf
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to
patients
March 12, 2025
Oncotarget, 2025, Vol.16, pp: 140-162
Precision Oncology Special
ABSTRACT
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity—including financial and time—are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN’s collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.
View the full article here: Download pdf
Oncotarget, 2025, Vol.16, pp: 140-162
Precision Oncology Special
ABSTRACT
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity—including financial and time—are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN’s collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.
View the full article here: Download pdf
Cure51 and Worldwide Innovative Network (WIN), in personalized cancer medicine consortium
November 12, 2024 - Cure51 and Worldwide Innovative Network (WIN), in personalized cancer medicine consortium have joined forces to bring cancer research to a new level, rallying the brightest oncologists, and academics in the world and leveraging data, cutting edge precision tech to make cancer a disease of the past.
WIN Consortium is a network of 39 world-class academic medical centers, industries, research organizations and patient advocates spanning 19 countries and 5 continents.
“We are excited to welcome Cure51 to WIN and we look forward to working with their focused, inspired and dynamic teams,” said Prof. Wafik S. El-Deiry, Chair of WIN Consortium, and Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University.
“Investigating exceptional cancer survivors is a brilliant idea and WIN network can contribute to this endeavor with our global footprint,” said Dr Razelle Kurzrock, Chief Medical Officer of WIN, Professor of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes Chair of Precision
Oncology.
“We are on a tireless mission to impact cancer in the next 10 years, and the partnership with WIN is a huge step
in the right direction,” says Cure51 co-founder Simon Istolainen, “We believe that cancer is a disease of the past, and with the best medical institutes in the world, we are building the tech to prove it. In a matter of years, we want every patient to become a miraculous survivor. Today, depending on the type of cancer 0.5% to 2% of patients survive aggressive cancers; we’re building a database of survivors to crack the survival code, which we know exists in nature, and drastically increase this ratio”.
View the full article here: Download pdf
WIN Consortium is a network of 39 world-class academic medical centers, industries, research organizations and patient advocates spanning 19 countries and 5 continents.
“We are excited to welcome Cure51 to WIN and we look forward to working with their focused, inspired and dynamic teams,” said Prof. Wafik S. El-Deiry, Chair of WIN Consortium, and Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University.
“Investigating exceptional cancer survivors is a brilliant idea and WIN network can contribute to this endeavor with our global footprint,” said Dr Razelle Kurzrock, Chief Medical Officer of WIN, Professor of Medicine, Associate Director Clinical Research, MCW Cancer Center and Linda T. & John A. Mellowes Chair of Precision
Oncology.
“We are on a tireless mission to impact cancer in the next 10 years, and the partnership with WIN is a huge step
in the right direction,” says Cure51 co-founder Simon Istolainen, “We believe that cancer is a disease of the past, and with the best medical institutes in the world, we are building the tech to prove it. In a matter of years, we want every patient to become a miraculous survivor. Today, depending on the type of cancer 0.5% to 2% of patients survive aggressive cancers; we’re building a database of survivors to crack the survival code, which we know exists in nature, and drastically increase this ratio”.
View the full article here: Download pdf